CYP2C19-IN-1

• UNSPSC Description:

  CYP2C19-IN-1 (compound 20d) is a potent CYP2C19 inhibitor, possessing no hepatotoxicity and ames toxicity. CYP2C19-IN-1 inhibits RNA-dependent RNA polymerase (RdRP) with a Ki value of 6.16 µM. CYP2C19-IN-1 can be used in study of anti-ZIKV[1].

• Target Antigen:

  Cytochrome P450; DNA/RNA Synthesis; Influenza Virus

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;Cell Cycle/DNA Damage;Metabolic Enzyme/Protease

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/cyp2c19-in-1.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=S(CC1=CC=C2C=C(C3=CC(N(C(N4)=O)C=CC4=O)=CC(C(C)(C)C)=C3OC)C=CC2=C1)(O)=O

• Molecular Weight:

  494.56

• References & Citations:

  [1]Ezeh M I, et al. Chemoinformatic Design and Profiling of Derivatives of Dasabuvir, Efavirenz, and Tipranavir as Potential Inhibitors of Zika Virus RNA-Dependent RNA Polymerase and Methyltransferase. ACS Omega, 2022 Sep 5.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  3010895-53-8